Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.

Biotechnology

Larimar Therapeutics

Larimar Therapeutics' headquarters in Bala Cynwyd, PA, United States

Carole Ben-Maimon

Frank Nazzario

Mohamed Hamdani

David Chu

Octavia Kane

Gopi Shankar

Keith E. Lynch, Jr.

Jennifer Johansson

Michael Celano

Tom Hamilton

Frank E. Thomas

Marni Joy Falk

Jill Ostrem

Joe Truitt

Jonathan Leff

Mark Payne

Giovanni Manfredi

The Research and Development team at Larimar Therapeutics is dedicated to advancing innovative therapies for complex rare diseases. Comprising scientists and clinical experts, the team focuses on the preclinical and clinical evaluation of their lead compound, CTI-1601, including conducting Phase 1 trials and ensuring regulatory compliance, while also exploring new research avenues to enhance treatment efficacy and patient outcomes.

Research and Development

The Leadership Team at Larimar Therapeutics is responsible for guiding the strategic direction and operational oversight of the company as it advances its innovative therapies for rare diseases. This team comprises key executives who collaborate to ensure regulatory compliance, financial stability, and clinical development success, while fostering a culture of innovation and accountability throughout the organization.

Leadership Team

The Finance and Administration team at Larimar Therapeutics plays a critical role in ensuring the company's financial health and operational efficiency. This team manages budgeting, financial reporting, and compliance, while also overseeing administrative functions to support the overall strategic goals of the organization. By collaborating closely with other departments, they facilitate resource allocation and provide strategic insights to drive informed decision-making.

Finance and Administration

The Clinical Operations team at Larimar Therapeutics is responsible for overseeing the planning, execution, and management of clinical trials to evaluate the safety and efficacy of its lead compound, CTI-1601. This team ensures compliance with regulatory requirements, coordinates with cross-functional stakeholders, and optimizes the supply chain for drug products and substances to support clinical programs. Their ultimate goal is to facilitate the successful advancement of therapies for rare diseases through efficient and effective clinical development processes.

Clinical Operations

The Regulatory and Quality Assurance team at Larimar Therapeutics is responsible for ensuring that the company's clinical development activities comply with regulatory standards and internal quality systems. This team monitors and documents processes related to drug development, manages submissions to regulatory agencies, and ensures that all quality assurance practices are upheld to facilitate the successful advancement of therapies like CTI-1601. Their work is critical in maintaining the integrity and compliance of clinical trials, ultimately supporting the company's mission to develop innovative treatments for rare diseases.

Larimar Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Finance and Administration

Clinical Operations

Regulatory and Quality Assurance

Offices

Larimar Therapeutics

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Finance and Administration

Clinical Operations

Regulatory and Quality Assurance

Offices

Related companies